Please login to the form below

Not currently logged in
Email:
Password:

diabetic macular edema

This page shows the latest diabetic macular edema news and features for those working in and with pharma, biotech and healthcare.

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.

Latest news

  • Roche’s Vabysmo recommended for EU approval by CHMP for sight loss Roche’s Vabysmo recommended for EU approval by CHMP for sight loss

    with neovascular macular degeneration (nAMD) and visual impairment caused by diabetic macular edema (DME).

  • Eylea growth closes the gap with Lucentis Eylea growth closes the gap with Lucentis

    Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... visual impairment due to macular oedema resulting from

  • Fresh approval for Roche's Lucentis as competition heats up Fresh approval for Roche's Lucentis as competition heats up

    drug. Lucentis (ranibizumab) has become the first medicine in the US to be cleared to treat diabetic retinopathy in people with diabetic macular edema (DME), which affects around 750, 000 Americans ... Lucentis' approval "gives patients with diabetic

  • Bayer files Eylea for diabetes complication in EU Bayer files Eylea for diabetes complication in EU

    Looks to keep with Novartis’ Lucentis. Bayer is trying to win approval for a third indication for its big-selling eye disease treatment Eylea, namely the treatment of diabetic macular edema ... DME). Eylea (aflibercept) - also known as VEGF Trap-Eye -

  • Lucentis cleared in Europe for pathological myopia Lucentis cleared in Europe for pathological myopia

    Lucentis was originally developed by Genentech - which has US marketing rights - and is already approved for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular ... edema secondary to retinal vein

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....